Cantor Fitzgerald Reiterates Overweight on Disc Medicine, Maintains $85 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Disc Medicine (NASDAQ:IRON) and maintained a price target of $85.
September 20, 2024 | 4:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Disc Medicine, maintaining a price target of $85, indicating confidence in the stock's potential.
The reiteration of an Overweight rating and a maintained price target of $85 by a reputable analyst suggests positive sentiment and potential upside for Disc Medicine's stock. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100